AAAAAA

   
Results: 1-10 |
Results: 10
IL-12 gene therapy of leukemia with hematopoietic progenitor cells withoutthe toxicity of systemic IL-12 treatment
Authors: Xu, YX Gao, XH Janakiraman, N Chapman, RA Gautam, SC
Citation: Yx. Xu et al., IL-12 gene therapy of leukemia with hematopoietic progenitor cells withoutthe toxicity of systemic IL-12 treatment, CLIN IMMUNO, 98(2), 2001, pp. 180-189
Therapy-related myelodysplastic syndrome (t-MDS) in a patient with anaplastic astrocytoma: Successful treatment with allogeneic bone marrow transplant
Authors: Rogers, LR Janakiraman, N Kasten-Sportes, C Rosenblum, ML
Citation: Lr. Rogers et al., Therapy-related myelodysplastic syndrome (t-MDS) in a patient with anaplastic astrocytoma: Successful treatment with allogeneic bone marrow transplant, J NEURO-ONC, 53(1), 2001, pp. 55-59
Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production
Authors: Gao, XH Xu, YX Janakiraman, N Chapman, RA Gautam, SC
Citation: Xh. Gao et al., Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production, BIOCH PHARM, 62(9), 2001, pp. 1299-1308
Interleukin-12 (IL-12) gene therapy of leukemia: Immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells
Authors: Gautam, SC Xu, YX Dumaguin, M Janakiraman, N Chapman, RA
Citation: Sc. Gautam et al., Interleukin-12 (IL-12) gene therapy of leukemia: Immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells, CANC GENE T, 7(7), 2000, pp. 1060-1068
Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging
Authors: Gautam, SC Xu, YX Dumaguin, M Janakiraman, N Chapman, RA
Citation: Sc. Gautam et al., Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging, BONE MAR TR, 25(6), 2000, pp. 639-645
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody
Authors: Wiseman, GA White, CA Witzig, TE Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy
Authors: Gautam, SC Xu, YX Pindolia, KR Yegappan, R Janakiraman, N Chapman, RA
Citation: Sc. Gautam et al., TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy, J HEMATOTH, 8(3), 1999, pp. 237-245
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed orrefractory low-grade or follicular non-Hodgkin's lymphoma
Authors: Piro, LD White, CA Grillo-Lopez, AJ Janakiraman, N Saven, A Beck, TM Varns, C Shuey, S Czuczman, M Lynch, JW Kolitz, JE Jain, V
Citation: Ld. Piro et al., Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed orrefractory low-grade or follicular non-Hodgkin's lymphoma, ANN ONCOL, 10(6), 1999, pp. 655-661
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma
Authors: Witzig, TE White, CA Wiseman, GA Gordon, LI Emmanouilides, C Raubitschek, A Janakiraman, N Gutheil, J Schilder, RJ Spies, S Silverman, DHS Parker, E Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803
Enhanced assessment of allogeneic bone marrow transplant engraftment usingautomated fluorescent-based typing
Authors: Pindolia, K Janakiraman, N Kasten-Sportes, C Demanet, C Van Waeyenberge, C Pals, G Worsham, MJ
Citation: K. Pindolia et al., Enhanced assessment of allogeneic bone marrow transplant engraftment usingautomated fluorescent-based typing, BONE MAR TR, 24(11), 1999, pp. 1235-1241
Risultati: 1-10 |